nach oben

Erschienen in:

16.01.2024 | REVIEW

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

verfasst von: Nasim Ebrahimi, Mahdokht Sadat Manavi, Ferdos Faghihkhorasani, Siavash Seifollahy Fakhr, Fatemeh Jafari Baei, Fereshteh Faghih Khorasani, Mohammad Mehdi Zare, Nazanin Pazhouhesh Far, Fatemeh Rezaei-Tazangi, Jun Ren, Russel J. Reiter, Noushin Nabavi, Amir Reza Aref, Chu Chen, Yavuz Nuri Ertas, Qi Lu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Epithelial-mesenchymal transition (EMT) is a complicated molecular process that governs cellular shape and function changes throughout tissue development and embryogenesis. In addition, EMT contributes to the development and spread of tumors. Expanding and degrading the surrounding microenvironment, cells undergoing EMT move away from the main location. On the basis of the expression of fibroblast-specific protein-1 (FSP1), fibroblast growth factor (FGF), collagen, and smooth muscle actin (-SMA), the mesenchymal phenotype exhibited in fibroblasts is crucial for promoting EMT. While EMT is not entirely reliant on its regulators like ZEB1/2, Twist, and Snail proteins, investigation of upstream signaling (like EGF, TGF-β, Wnt) is required to get a more thorough understanding of tumor EMT. Throughout numerous cancers, connections between tumor epithelial and fibroblast cells that influence tumor growth have been found. The significance of cellular crosstalk stems from the fact that these events affect therapeutic response and disease prognosis. This study examines how classical EMT signals emanating from various cancer cells interfere to tumor metastasis, treatment resistance, and tumor recurrence.

Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. Nature, 575, 299–309. https://doi.org/10.1038/s41586-019-1730-1CrossRefPubMedPubMedCentral

Yaray, K., Norbakhsh, A., Rashidzadeh, H., Mohammadi, A., Mozafari, F., Ghaffarlou, M., Mousazadeh, N., Ghaderzadeh, R., Ghorbani, Y., Nasehi, L., et al. (2023). Chemoradiation therapy of 4T1 cancer cells with methotrexate conjugated platinum nanoparticles under X-Ray irradiation. Inorganic Chemistry Communications, 150, 110457. https://doi.org/10.1016/j.inoche.2023.110457CrossRef

Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019). The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates, 46, 100645. https://doi.org/10.1016/j.drup.2019.100645CrossRefPubMed

Ashrafizadeh, M., Mirzaei, S., Hashemi, F., Zarrabi, A., Zabolian, A., Saleki, H., Sharifzadeh, S. O., Soleymani, L., Daneshi, S., & Hushmandi, K. (2021). New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomedicine & Pharmacotherapy, 141, 111824.CrossRef

Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Kalantari, M., Mohammadinejad, R., Javaheri, T., & Sethi, G. (2020). Association of the epithelial–mesenchymal transition (EMT) with cisplatin resistance. International journal of Molecular Sciences, 21, 4002.CrossRefPubMedPubMedCentral

Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020). Guidelines and definitions for research on epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 21, 341–352. https://doi.org/10.1038/s41580-020-0237-9CrossRefPubMedPubMedCentral

Mirzaei, S., Abadi, A. J., Gholami, M. H., Hashemi, F., Zabolian, A., Hushmandi, K., Zarrabi, A., Entezari, M., Aref, A. R., & Khan, H. (2021). The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets. European Journal of Pharmacology, 908, 174344.CrossRefPubMed

Olmeda, D., Moreno-Bueno, G., Flores, J. M., Fabra, A., Portillo, F., & Cano, A. (2007). SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Research, 67, 11721–11731. https://doi.org/10.1158/0008-5472.Can-07-2318CrossRefPubMed

Nosrati, H., Salehiabar, M., Charmi, J., Yaray, K., Ghaffarlou, M., Balcioglu, E., & Ertas, Y. N. (2023). Enhanced in vivo radiotherapy of breast cancer using gadolinium oxide and gold hybrid nanoparticles. ACS Applied Bio Materials, 6, 784–792. https://doi.org/10.1021/acsabm.2c00965CrossRefPubMedPubMedCentral

10.

Ashrafizadeh, M., Hushmandi, K., Hashemi, M., Akbari, M. E., Kubatka, P., Raei, M., Koklesova, L., Shahinozzaman, M., Mohammadinejad, R., & Najafi, M. (2020). Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancer. Biomolecules, 10, 1159.CrossRefPubMedPubMedCentral

11.

Mirzaei, S., Gholami, M. H., Aghdaei, H. A., Hashemi, M., Parivar, K., Karamian, A., Zarrabi, A., Ashrafizadeh, M., & Lu, J. (2023). Exosome-mediated miR-200a delivery into TGF-β-treated AGS cells abolished epithelial-mesenchymal transition with normalization of ZEB1, vimentin and Snail1 expression. Environmental Research, 231, 116115.CrossRefPubMed

12.

Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. Nature Reviews Drug Discovery, 19, 39–56. https://doi.org/10.1038/s41573-019-0044-1CrossRefPubMed

13.

Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019). Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 24, 65–78. https://doi.org/10.1016/j.stem.2018.11.011CrossRefPubMed

14.

Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020). Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates, 53, 100715. https://doi.org/10.1016/j.drup.2020.100715CrossRefPubMed

15.

Barriere, G., Fici, P., Gallerani, G., Fabbri, F., & Rigaud, M. (2015). Epithelial mesenchymal transition: A double-edged sword. Clinical and Translational Medicine, 4, 14. https://doi.org/10.1186/s40169-015-0055-4CrossRefPubMedPubMedCentral

16.

Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. E. M. T. (2016). Cell, 2016(166), 21–45. https://doi.org/10.1016/j.cell.2016.06.028CrossRef

17.

Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 15, 178–196. https://doi.org/10.1038/nrm3758CrossRefPubMedPubMedCentral

18.

Peinado, H., Olmeda, D., & Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nature Reviews Cancer, 7, 415–428. https://doi.org/10.1038/nrc2131CrossRefPubMed

19.

Kang, Y., & Massagué, J. (2004). Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell, 118, 277–279. https://doi.org/10.1016/j.cell.2004.07.011CrossRefPubMed

20.

Wick, W., Platten, M., & Weller, M. (2001). Glioma cell invasion: Regulation of metalloproteinase activity by TGF-beta. Journal of Neuro-oncology, 53, 177–185. https://doi.org/10.1023/a:1012209518843CrossRefPubMed

21.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119, 1420–1428. https://doi.org/10.1172/jci39104CrossRefPubMedPubMedCentral

22.

Ocaña, O. H., Córcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., & Nieto, M. A. (2012). Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell, 22, 709–724. https://doi.org/10.1016/j.ccr.2012.10.012CrossRefPubMed

23.

Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22, 725–736. https://doi.org/10.1016/j.ccr.2012.09.022CrossRefPubMedPubMedCentral

24.

Shibue, T., Brooks, M. W., & Weinberg, R. A. (2013). An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell, 24, 481–498. https://doi.org/10.1016/j.ccr.2013.08.012CrossRefPubMed

25.

Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018). The challenge of drug resistance in cancer treatment: A current overview. Clinical & Experimental Metastasis, 35, 309–318. https://doi.org/10.1007/s10585-018-9903-0CrossRef

26.

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: An overview. Cancers (Basel), 6, 1769–1792. https://doi.org/10.3390/cancers6031769CrossRefPubMed

27.

Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C. C., LeBleu, V. S., & Kalluri, R. (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature, 527, 525–530. https://doi.org/10.1038/nature16064CrossRefPubMedPubMedCentral

28.

Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015). Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 527, 472–476. https://doi.org/10.1038/nature15748CrossRefPubMedPubMedCentral

29.

Huang, J., Li, H., & Ren, G. (2015). Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). International Journal of Oncology, 47, 840–848. https://doi.org/10.3892/ijo.2015.3084CrossRefPubMed

30.

Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011). Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death & Disease, 2, e179. https://doi.org/10.1038/cddis.2011.61CrossRef

31.

Sommers, C. L., Heckford, S. E., Skerker, J. M., Worland, P., Torri, J. A., Thompson, E. W., Byers, S. W., & Gelmann, E. P. (1992). Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Research, 52, 5190–5197.PubMed

32.

Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015). SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clinical Cancer Research, 21, 4686–4697. https://doi.org/10.1158/1078-0432.Ccr-14-3319CrossRefPubMed

33.

Adelian, S., Ahadi, A. M., Ayat, H., & Teimori, H. (2020). Enhanced recombinant C-terminal domain of gli2 gene expression can improve wound healing through promoting cdc25b and N-Myc genes expression. Gene Reports, 20, 100754. https://doi.org/10.1016/j.genrep.2020.100754CrossRef

34.

Park, S. H., Jo, M. J., Kim, B. R., Jeong, Y. A., Na, Y. J., Kim, J. L., Jeong, S., Yun, H. K., Kim, D. Y., Kim, B. G., et al. (2019). Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics, 9, 2235–2251. https://doi.org/10.7150/thno.30678CrossRefPubMedPubMedCentral

35.

Li, J., Liu, H., Yu, J., & Yu, H. (2015). Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Molecular Medicine Reports, 12, 192–198. https://doi.org/10.3892/mmr.2015.3356CrossRefPubMedPubMedCentral

36.

Katsuno, Y., Meyer, D. S., Zhang, Z., Shokat, K. M., Akhurst, R. J., Miyazono, K., & Derynck, R. (2019). Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Science Signaling, 12, 570. https://doi.org/10.1126/scisignal.aau8544

37.

Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research, 69, 2400–2407. https://doi.org/10.1158/0008-5472.Can-08-4312CrossRefPubMedPubMedCentral

38.

Wu, Y., Ginther, C., Kim, J., Mosher, N., Chung, S., Slamon, D., & Vadgama, J. V. (2012). Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Molecular Cancer Research, 10, 1597–1606. https://doi.org/10.1158/1541-7786.Mcr-12-0155-tCrossRefPubMed

39.

Wang, X., Ling, M. T., Guan, X. Y., Tsao, S. W., Cheung, H. W., Lee, D. T., & Wong, Y. C. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene, 23, 474–482. https://doi.org/10.1038/sj.onc.1207128CrossRefPubMed

40.

Chen, Y., Li, L., Zeng, J., Wu, K., Zhou, J., Guo, P., Zhang, D., Xue, Y., Liang, L., Wang, X., et al. (2012). Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy, 58, 264–272. https://doi.org/10.1159/000341860CrossRefPubMed

41.

Li, N., Babaei-Jadidi, R., Lorenzi, F., Spencer-Dene, B., Clarke, P., Domingo, E., Tulchinsky, E., Vries, R. G. J., Kerr, D., Pan, Y., et al. (2019). An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis, 8, 13. https://doi.org/10.1038/s41389-019-0125-3CrossRefPubMedPubMedCentral

42.

Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013). The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Molecular Medicine, 5, 1196–1212. https://doi.org/10.1002/emmm.201302827CrossRefPubMedPubMedCentral

43.

Ma, X., Wang, B., Wang, X., Luo, Y., & Fan, W. (2018). NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells. PLoS One, 13, e0192436. https://doi.org/10.1371/journal.pone.0192436CrossRefPubMedPubMedCentral

44.

Li, R. N., Liu, B., Li, X. M., Hou, L. S., Mu, X. L., Wang, H., & Linghu, H. (2017). DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy. Science and Reports, 7, 9285. https://doi.org/10.1038/s41598-017-08249-7CrossRef

45.

Deng, J. J., Zhang, W., Xu, X. M., Zhang, F., Tao, W. P., Ye, J. J., & Ge, W. (2016). Twist mediates an aggressive phenotype in human colorectal cancer cells. International Journal of Oncology, 48, 1117–1124. https://doi.org/10.3892/ijo.2016.3342CrossRefPubMed

46.

Hill, C., & Wang, Y. (2020). The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance. Cancer Drug Resistance, 3, 38–47. https://doi.org/10.20517/cdr.2019.75CrossRefPubMedPubMedCentral

47.

Hojo, N., Huisken, A. L., Wang, H., Chirshev, E., Kim, N. S., Nguyen, S. M., Campos, H., Glackin, C. A., Ioffe, Y. J., & Unternaehrer, J. J. (2018). Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer. Science and Reports, 8, 8704. https://doi.org/10.1038/s41598-018-27021-zCrossRef

48.

Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012). EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12, 91. https://doi.org/10.1186/1471-2407-12-91CrossRefPubMedPubMedCentral

49.

De Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer, 13, 97–110. https://doi.org/10.1038/nrc3447CrossRefPubMed

50.

Xu, J., Lamouille, S., & Derynck, R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Research, 19, 156–172. https://doi.org/10.1038/cr.2009.5CrossRefPubMed

51.

Yang, F., Sun, L., Li, Q., Han, X., Lei, L., Zhang, H., & Shang, Y. (2012). SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO Journal, 31, 110–123. https://doi.org/10.1038/emboj.2011.364CrossRefPubMed

52.

Yang, M. H., Hsu, D. S., Wang, H. W., Wang, H. J., Lan, H. Y., Yang, W. H., Huang, C. H., Kao, S. Y., Tzeng, C. H., Tai, S. K., et al. (2010). Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nature Cell Biology, 12, 982–992. https://doi.org/10.1038/ncb2099CrossRefPubMed

53.

Farge, E. (2003). Mechanical induction of Twist in the Drosophila foregut/stomodeal primordium. Current Biology, 13, 1365–1377. https://doi.org/10.1016/s0960-9822(03)00576-1CrossRefPubMed

54.

Kang, Y., Chen, C. R., & Massagué, J. (2003). A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Molecular Cell, 11, 915–926. https://doi.org/10.1016/s1097-2765(03)00109-6CrossRefPubMed

55.

Hong, J., Zhou, J., Fu, J., He, T., Qin, J., Wang, L., Liao, L., & Xu, J. (2011). Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Research, 71, 3980–3990. https://doi.org/10.1158/0008-5472.Can-10-2914CrossRefPubMedPubMedCentral

56.

Sánchez-Tilló, E., Lázaro, A., Torrent, R., Cuatrecasas, M., Vaquero, E. C., Castells, A., Engel, P., & Postigo, A. (2010). ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene, 29, 3490–3500. https://doi.org/10.1038/onc.2010.102CrossRefPubMed

57.

Dave, N., Guaita-Esteruelas, S., Gutarra, S., Frias, À., Beltran, M., Peiró, S., & de Herreros, A. G. (2011). Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. Journal of Biological Chemistry, 286, 12024–12032. https://doi.org/10.1074/jbc.M110.168625CrossRefPubMedPubMedCentral

58.

Shirakihara, T., Saitoh, M., & Miyazono, K. (2007). Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Molecular Biology of the Cell, 18, 3533–3544. https://doi.org/10.1091/mbc.e07-03-0249CrossRefPubMedPubMedCentral

59.

Long, J., Zuo, D., & Park, M. (2005). Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. Journal of Biological Chemistry, 280, 35477–35489. https://doi.org/10.1074/jbc.M504477200CrossRefPubMed

60.

Bao, Z., Zeng, W., Zhang, D., Wang, L., Deng, X., Lai, J., Li, J., Gong, J., & Xiang, G. (2022). SNAIL induces EMT and lung metastasis of tumours secreting CXCL2 to promote the invasion of M2-type immunosuppressed macrophages in colorectal cancer. International Journal of Biological Sciences, 18, 2867.CrossRefPubMedPubMedCentral

61.

Wang, W.-D., Shang, Y., Li, Y., & Chen, S.-Z. (2019). Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation. Acta Pharmacologica Sinica, 40, 1219–1227.CrossRefPubMedPubMedCentral

62.

Dong, C., Wu, Y., Yao, J., Wang, Y., Yu, Y., Rychahou, P. G., Evers, B. M., & Zhou, B. P. (2012). G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. The Journal of Clinical Investigation, 122, 1469–1486. https://doi.org/10.1172/jci57349CrossRefPubMedPubMedCentral

63.

Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 125, 315–326. https://doi.org/10.1016/j.cell.2006.02.041CrossRefPubMed

64.

Kao, S. H., Wang, W. L., Chen, C. Y., Chang, Y. L., Wu, Y. Y., Wang, Y. T., Wang, S. P., Nesvizhskii, A. I., Chen, Y. J., Hong, T. M., et al. (2014). GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene, 33, 3172–3182. https://doi.org/10.1038/onc.2013.279CrossRefPubMed

65.

Du, D., Katsuno, Y., Meyer, D., Budi, E. H., Chen, S. H., Koeppen, H., Wang, H., Akhurst, R. J., & Derynck, R. (2018). Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelial-mesenchymal transition. EMBO Reports, 19, 135–155. https://doi.org/10.15252/embr.201744250CrossRefPubMed

66.

Du, C., Zhang, C., Hassan, S., Biswas, M. H., & Balaji, K. C. (2010). Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Research, 70, 7810–7819. https://doi.org/10.1158/0008-5472.Can-09-4481CrossRefPubMed

67.

Wang, S. P., Wang, W. L., Chang, Y. L., Wu, C. T., Chao, Y. C., Kao, S. H., Yuan, A., Lin, C. W., Yang, S. C., Chan, W. K., et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biology, 11, 694–704. https://doi.org/10.1038/ncb1875CrossRefPubMed

68.

Xu, X., Zhang, L., He, X., Zhang, P., Sun, C., Xu, X., Lu, Y., & Li, F. (2018). TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochemical and Biophysical Research Communications, 502, 160–165. https://doi.org/10.1016/j.bbrc.2018.05.139CrossRefPubMed

69.

Oshimori, N., Oristian, D., & Fuchs, E. (2015). TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell, 160, 963–976. https://doi.org/10.1016/j.cell.2015.01.043CrossRefPubMedPubMedCentral

70.

Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018). Non-coding RNA networks in cancer. Nature Reviews Cancer, 18, 5–18. https://doi.org/10.1038/nrc.2017.99CrossRefPubMed

71.

Singh, A., Malvankar, S., Ravi Kumar, Y. S., Seervi, M., Srivastava, R. K., & Verma, B. (2022). Role of various non-coding RNAs in EMT, cancer, and metastasis: Recent trends and future perspective. Advances in Cancer Biology - Metastasis, 4, 100039. https://doi.org/10.1016/j.adcanc.2022.100039CrossRef

72.

Madhry, D., Pandey, K. K., Kaur, J., Rawat, Y., Sapra, L., Ravikumar, Y. S., Srivastava, R. K., Bhattacharyya, S., & Verma, B. (2021). Role of non-coding RNAs in Dengue virus-host interaction. Frontiers in Bioscience-Scholar, 13(44), 55.

73.

Mazarei, M., Shahabi Rabori, V., Ghasemi, N., Salehi, M., Rayatpisheh, N., Jahangiri, N., & Saberiyan, M. (2023). LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-023-01179-xCrossRefPubMed

74.

Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6, 857–866. https://doi.org/10.1038/nrc1997CrossRefPubMed

75.

Shen, Y., Zhou, J., Li, Y., Ye, F., Wan, X., Lu, W., Xie, X., & Cheng, X. (2014). miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS One, 9, e109299. https://doi.org/10.1371/journal.pone.0109299CrossRefPubMedPubMedCentral

76.

Ren, L. L., Yan, T. T., Shen, C. Q., Tang, J. Y., Kong, X., Wang, Y. C., Chen, J., Liu, Q., He, J., Zhong, M., et al. (2018). The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. Cell Death & Disease, 9, 687. https://doi.org/10.1038/s41419-018-0732-5CrossRef

77.

Su, W., Xu, M., Chen, X., Chen, N., Gong, J., Nie, L., Li, L., Li, X., Zhang, M., & Zhou, Q. (2017). Long noncoding RNA ZEB1-AS1 epigenetically regulates the expressions of ZEB1 and downstream molecules in prostate cancer. Molecular Cancer, 16, 142. https://doi.org/10.1186/s12943-017-0711-yCrossRefPubMedPubMedCentral

78.

Deng, S. J., Chen, H. Y., Ye, Z., Deng, S. C., Zhu, S., Zeng, Z., He, C., Liu, M. L., Huang, K., Zhong, J. X., et al. (2018). Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene, 37, 5811–5828. https://doi.org/10.1038/s41388-018-0382-1CrossRefPubMed

79.

Xue, D., Wang, H., Chen, Y., Shen, D., Lu, J., Wang, M., Zebibula, A., Xu, L., Wu, H., Li, G., et al. (2019). Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Molecular Cancer, 18, 151. https://doi.org/10.1186/s12943-019-1072-5CrossRefPubMedPubMedCentral

80.

Wei, S., Zheng, Y., Jiang, Y., Li, X., Geng, J., Shen, Y., Li, Q., Wang, X., Zhao, C., Chen, Y., et al. (2019). The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p. eBioMedicine, 44, 182–193. https://doi.org/10.1016/j.ebiom.2019.05.032CrossRefPubMedPubMedCentral

81.

Yang, Z., Qu, C. B., Zhang, Y., Zhang, W. F., Wang, D. D., Gao, C. C., Ma, L., Chen, J. S., Liu, K. L., Zheng, B., et al. (2019). Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene, 38, 2516–2532. https://doi.org/10.1038/s41388-018-0602-8CrossRefPubMed

82.

Yang, H., Li, X., Meng, Q., Sun, H., Wu, S., Hu, W., Liu, G., Li, X., Yang, Y., & Chen, R. (2020). CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Molecular Cancer, 19, 13. https://doi.org/10.1186/s12943-020-1139-3CrossRefPubMedPubMedCentral

83.

Khanbabaei, H., Ebrahimi, S., García-Rodríguez, J. L., Ghasemi, Z., Pourghadamyari, H., Mohammadi, M., & Kristensen, L. S. (2022). Non-coding RNAs and epithelial mesenchymal transition in cancer: Molecular mechanisms and clinical implications. Journal of Experimental & Clinical Cancer Research, 41, 278. https://doi.org/10.1186/s13046-022-02488-xCrossRef

84.

Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021). EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Communications (Lond), 41, 199–217. https://doi.org/10.1002/cac2.12138CrossRef

85.

Lu, H. Y., Zu, Y. X., Jiang, X. W., Sun, X. T., Liu, T. Y., Li, R. L., Wu, Q., Zhang, Y. S., & Zhao, Q. C. (2019). Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. Pharmacological Research, 148, 104406. https://doi.org/10.1016/j.phrs.2019.104406CrossRefPubMed

86.

Blazquez, R., Rietkötter, E., Wenske, B., Wlochowitz, D., Sparrer, D., Vollmer, E., Müller, G., Seegerer, J., Sun, X., Dettmer, K., et al. (2020). LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer. International Journal of Cancer, 146, 3170–3183. https://doi.org/10.1002/ijc.32742CrossRefPubMed

87.

Kahlert, U. D., Nikkhah, G., & Maciaczyk, J. (2013). Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Letters, 331, 131–138. https://doi.org/10.1016/j.canlet.2012.12.010CrossRefPubMed

88.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704–715. https://doi.org/10.1016/j.cell.2008.03.027CrossRefPubMedPubMedCentral

89.

Zarkoob, H., Taube, J. H., Singh, S. K., Mani, S. A., & Kohandel, M. (2013). Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS One, 8, e64169. https://doi.org/10.1371/journal.pone.0064169CrossRefPubMedPubMedCentral

90.

Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. (2013). Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell, 24, 331–346. https://doi.org/10.1016/j.ccr.2013.08.001CrossRefPubMed

91.

Ye, X. Z., Xu, S. L., Xin, Y. H., Yu, S. C., Ping, Y. F., Chen, L., Xiao, H. L., Wang, B., Yi, L., Wang, Q. L., et al. (2012). Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. The Journal of Immunology, 189, 444–453. https://doi.org/10.4049/jimmunol.1103248CrossRefPubMed

92.

Iwadate, Y. (2016). Epithelial-mesenchymal transition in glioblastoma progression. Oncology Letters, 11, 1615–1620. https://doi.org/10.3892/ol.2016.4113CrossRefPubMedPubMedCentral

93.

Mikheeva, S. A., Mikheev, A. M., Petit, A., Beyer, R., Oxford, R. G., Khorasani, L., Maxwell, J. P., Glackin, C. A., Wakimoto, H., González-Herrero, I., et al. (2010). TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Molecular Cancer, 9, 194. https://doi.org/10.1186/1476-4598-9-194CrossRefPubMedPubMedCentral

94.

Nagaishi, M., Paulus, W., Brokinkel, B., Vital, A., Tanaka, Y., Nakazato, Y., Giangaspero, F., & Ohgaki, H. (2012). Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathology, 22, 670–676. https://doi.org/10.1111/j.1750-3639.2012.00571.xCrossRefPubMedPubMedCentral

95.

Zhong, C., Tao, B., Chen, Y., Guo, Z., Yang, X., Peng, L., Xia, X., & Chen, L. (2020). B7–H3 regulates glioma growth and cell invasion through a JAK2/STAT3/Slug-dependent signaling pathway. OncoTargets and therapy, 13, 2215.CrossRefPubMedPubMedCentral

96.

Wang, Q., Li, X., Zhu, Y., & Yang, P. (2014). MicroRNA-16 suppresses epithelial-mesenchymal transition-related gene expression in human glioma. Molecular Medicine Reports, 10, 3310–3314. https://doi.org/10.3892/mmr.2014.2583CrossRefPubMed

97.

Edwards, L. A., Woolard, K., Son, M. J., Li, A., Lee, J., Ene, C., Mantey, S. A., Maric, D., Song, H., Belova, G., et al. (2011). Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. Journal of the National Cancer Institute, 103, 1162–1178. https://doi.org/10.1093/jnci/djr224CrossRefPubMedPubMedCentral

98.

Pastushenko, I., & Blanpain, C. (2019). EMT transition states during tumor progression and metastasis. Trends in Cell Biology, 29, 212–226. https://doi.org/10.1016/j.tcb.2018.12.001CrossRefPubMed

99.

Paul, I., Bhattacharya, S., Chatterjee, A., & Ghosh, M. K. (2013). Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes & Cancer, 4, 427–446. https://doi.org/10.1177/1947601913503341CrossRef

100.

Sandberg, C. J., Altschuler, G., Jeong, J., Strømme, K. K., Stangeland, B., Murrell, W., Grasmo-Wendler, U. H., Myklebost, O., Helseth, E., Vik-Mo, E. O., et al. (2013). Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. Experimental Cell Research, 319, 2230–2243. https://doi.org/10.1016/j.yexcr.2013.06.004CrossRefPubMed

101.

Clevers, H., Loh, K. M., & Nusse, R. (2014). Stem cell signaling An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science, 346, 1248012. https://doi.org/10.1126/science.1248012CrossRefPubMed

102.

Gong, A., & Huang, S. (2012). FoxM1 and Wnt/β-catenin signaling in glioma stem cells. Cancer Research, 72, 5658–5662. https://doi.org/10.1158/0008-5472.Can-12-0953CrossRefPubMedPubMedCentral

103.

Jin, X., Jeon, H. Y., Joo, K. M., Kim, J. K., Jin, J., Kim, S. H., Kang, B. G., Beck, S., Lee, S. J., Kim, J. K., et al. (2011). Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Research, 71, 3066–3075. https://doi.org/10.1158/0008-5472.Can-10-1495CrossRefPubMed

104.

Ebrahimi, N., Adelian, S., Shakerian, S., Afshinpour, M., Chaleshtori, S. R., Rostami, N., Rezaei-Tazangi, F., Beiranvand, S., Hamblin, M. R., & Aref, A. R. (2022). Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy. Cytokine & Growth Factor Reviews, 64, 33–45. https://doi.org/10.1016/j.cytogfr.2022.01.006CrossRef

105.

Brabletz, S., Bajdak, K., Meidhof, S., Burk, U., Niedermann, G., Firat, E., Wellner, U., Dimmler, A., Faller, G., Schubert, J., et al. (2011). The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO Journal, 30, 770–782. https://doi.org/10.1038/emboj.2010.349CrossRefPubMedPubMedCentral

106.

Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y. M., Maciaczyk, J., et al. (2010). NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 28, 5–16. https://doi.org/10.1002/stem.254CrossRefPubMed

107.

Kristoffersen, K., Villingshøj, M., Poulsen, H. S., & Stockhausen, M. T. (2013). Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biology & Therapy, 14, 625–637. https://doi.org/10.4161/cbt.24595CrossRef

108.

Si, D., Yin, F., Peng, J., & Zhang, G. (2020). High expression of CD44 predicts a poor prognosis in glioblastomas. Cancer Management and Research, 12, 769–775. https://doi.org/10.2147/cmar.S233423CrossRefPubMedPubMedCentral

109.

Kolliopoulos, C., Ali, M. M., Castillejo-Lopez, C., Heldin, C. H., & Heldin, P. (2022). CD44 Depletion in glioblastoma cells suppresses growth and stemness and induces senescence. Cancers (Basel), 14, 3747. https://doi.org/10.3390/cancers14153747CrossRefPubMed

110.

Xu, F., Shangguan, X., Pan, J., Yue, Z., Shen, K., Ji, Y., Zhang, W., Zhu, Y., Sha, J., Wang, Y., et al. (2021). HOXD13 suppresses prostate cancer metastasis and BMP4-induced epithelial-mesenchymal transition by inhibiting SMAD1. International Journal of Cancer, 148, 3060–3070. https://doi.org/10.1002/ijc.33494CrossRefPubMed

111.

Liu, C., Wang, L., Liu, X., Tan, Y., Tao, L., Xiao, Y., Deng, P., Wang, H., Deng, Q., Lin, Y., et al. (2021). Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation. Theranostics, 11, 2966–2986. https://doi.org/10.7150/thno.48699CrossRefPubMedPubMedCentral

112.

Xie, S. Y., Shi, D. B., Ouyang, Y., Lin, F., Chen, X. Y., Jiang, T. C., Xia, W., Guo, L., & Lin, H. X. (2022). SHMT2 promotes tumor growth through VEGF and MAPK signaling pathway in breast cancer. American Journal of Cancer Research, 12, 3405–3421.PubMedPubMedCentral

113.

Chen, L., Liu, H., Ji, Y., Ma, Z., Shen, K., Shangguan, X., Qian, H., Zhao, Y., Pan, C. W., & Xue, W. (2022). Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition. Experimental Cell Research, 415, 113138. https://doi.org/10.1016/j.yexcr.2022.113138CrossRefPubMed

114.

Jiang, S., Zhu, Y., Chen, Z., Huang, Z., Liu, B., Xu, Y., Li, Z., Lin, Z., & Li, M. (2021). S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway. Human Cell, 34, 1215–1226. https://doi.org/10.1007/s13577-021-00538-8CrossRefPubMed

115.

Papanikolaou, S., Vourda, A., Syggelos, S., & Gyftopoulos, K. (2021). Cell plasticity and prostate cancer: The role of epithelial-mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance. Cancers (Basel), 13, 2795. https://doi.org/10.3390/cancers13112795CrossRefPubMed

116.

Chen, B., Liu, C., Bai, G., Zhu, Y., & Xu, H. (2021). BTBD7 accelerates the epithelial-mesenchymal transition, proliferation and invasion of prostate cancer cells. Journal of B.U.ON., 26, 2111–2116.PubMed

117.

Scala, S. (2015). Molecular pathways: Targeting the CXCR4-CXCL12 axis–Untapped potential in the tumor microenvironment. Clinical Cancer Research, 21, 4278–4285. https://doi.org/10.1158/1078-0432.Ccr-14-0914CrossRefPubMed

118.

Hernandez, L., Magalhaes, M. A., Coniglio, S. J., Condeelis, J. S., & Segall, J. E. (2011). Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Research, 13, R128. https://doi.org/10.1186/bcr3074CrossRefPubMedPubMedCentral

119.

Saha, A., Ahn, S., Blando, J., Su, F., Kolonin, M. G., & DiGiovanni, J. (2017). Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives myc-induced prostate cancer in obese mice. Cancer Research, 77, 5158–5168. https://doi.org/10.1158/0008-5472.Can-17-0284CrossRefPubMedPubMedCentral

120.

Ahn, S., Saha, A., Clark, R., Kolonin, M. G., & DiGiovanni, J. (2022). CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells. Oncogene, 41, 4633–4644. https://doi.org/10.1038/s41388-022-02466-9CrossRefPubMed

121.

Zhang, B., Li, Y., Wu, Q., Xie, L., Barwick, B., Fu, C., Li, X., Wu, D., Xia, S., Chen, J., et al. (2021). Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature Communications, 12, 1714. https://doi.org/10.1038/s41467-021-21976-wCrossRefPubMedPubMedCentral

122.

Li, L., Sun, F., Chen, X., & Zhang, M. (2018). ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis. Oncotargets and Therapy, 11, 781–789. https://doi.org/10.2147/ott.S144241CrossRefPubMedPubMedCentral

123.

Zhang, Y., Wang, L., Gao, P., Sun, Z., Li, N., Lu, Y., Shen, J., Sun, J., Yang, Y., Dai, H., et al. (2018). ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells. International Journal of Molecular Medicine, 42, 2343–2352. https://doi.org/10.3892/ijmm.2018.3842CrossRefPubMedPubMedCentral

124.

Choi, J. D., Kim, T. J., Jeong, B. C., Jeon, H. G., Jeon, S. S., Kang, M. Y., Yeom, S. Y., & Seo, S. I. (2021). ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). Science and Reports, 11, 21984. https://doi.org/10.1038/s41598-021-01003-0CrossRef

125.

Marín-Aguilera, M., Codony-Servat, J., Reig, Ò., Lozano, J. J., Fernández, P. L., Pereira, M. V., Jiménez, N., Donovan, M., Puig, P., Mengual, L., et al. (2014). Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Molecular Cancer Therapeutics, 13, 1270–1284. https://doi.org/10.1158/1535-7163.Mct-13-0775CrossRefPubMed

126.

Børretzen, A., Gravdal, K., Haukaas, S. A., Beisland, C., Akslen, L. A., & Halvorsen, O. J. (2019). FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The Journal of Pathology: Clinical Research, 5, 272–286. https://doi.org/10.1002/cjp2.142CrossRefPubMedPubMedCentral

127.

Shiota, M., Itsumi, M., Takeuchi, A., Imada, K., Yokomizo, A., Kuruma, H., Inokuchi, J., Tatsugami, K., Uchiumi, T., Oda, Y., et al. (2015). Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Endocrine-Related Cancer, 22, 889–900. https://doi.org/10.1530/erc-15-0225CrossRefPubMed

128.

Peng, J., He, Z., Yuan, Y., Xie, J., Zhou, Y., Guo, B., & Guo, J. (2022). Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells. Cell Communication and Signaling: CCS, 20, 194. https://doi.org/10.1186/s12964-022-00950-zCrossRefPubMedPubMedCentral

129.

Zhao, X., Liu, X., Hu, S., Pan, Y., Zhang, J., Tai, G., & Shao, C. (2022). GDF15 contributes to radioresistance by mediating the EMT and stemness of breast cancer cells. International Journal of Molecular Sciences, 23, 10911. https://doi.org/10.3390/ijms231810911CrossRefPubMedPubMedCentral

130.

Qian, J., Shen, S., Chen, W., & Chen, N. (2018). Propofol reversed hypoxia-induced docetaxel resistance in prostate cancer cells by preventing epithelial-mesenchymal transition by inhibiting hypoxia-inducible factor 1α. BioMed Research International, 2018, 4174232. https://doi.org/10.1155/2018/4174232CrossRefPubMedPubMedCentral

131.

Sun, X. Y., Li, H. Z., Xie, D. F., Gao, S. S., Huang, X., Guan, H., Bai, C. J., & Zhou, P. K. (2022). LPAR5 confers radioresistance to cancer cells associated with EMT activation via the ERK/Snail pathway. Journal of Translational Medicine, 20, 456. https://doi.org/10.1186/s12967-022-03673-4CrossRefPubMedPubMedCentral

132.

Yadav, S., Kowolik, C. M., Lin, M., Zuro, D., Hui, S. K., Riggs, A. D., & Horne, D. A. (2019). SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties. Molecular Carcinogenesis, 58, 113–125. https://doi.org/10.1002/mc.22913CrossRefPubMed

133.

Hao, H., Chen, H., Xie, L., & Liu, H. (2021). YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition. Annals of Medicine, 53, 1170–1178. https://doi.org/10.1080/07853890.2021.1950920CrossRefPubMed

134.

Wei, H., Wang, J., Li, W., Ma, R., Xu, Z., Luo, Z., Lu, Y., Zhang, X., Long, X., Pu, J., et al. (2019). The underlying pathophysiology association between the type 2-diabetic and hepatocellular carcinoma. Journal of Cellular Physiology, 234, 10835–10841. https://doi.org/10.1002/jcp.27919CrossRefPubMed

135.

Zhang, H., Wei, X., Lu, S., Lin, X., Huang, J., Chen, L., Huang, X., Jiang, L., Li, Y., Qin, L., et al. (2019). Protective effect of DMDD, isolated from the root of Averrhoa carambola L., on high glucose induced EMT in HK-2 cells by inhibiting the TLR4-BAMBI-Smad2/3 signaling pathway. Biomedicine & Pharmacotherapy, 113, 108705. https://doi.org/10.1016/j.biopha.2019.108705CrossRef

136.

Li, S., Zhu, H., Chen, H., Xia, J., Zhang, F., Xu, R., & Lin, Q. (2020). Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. Journal of Cellular and Molecular Medicine, 24, 10391–10401. https://doi.org/10.1111/jcmm.15653CrossRefPubMedPubMedCentral

137.

Migita, T., Ueda, A., Ohishi, T., Hatano, M., Seimiya, H., Horiguchi, S. I., Koga, F., & Shibasaki, F. (2017). Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Laboratory Investigation, 97, 567–576. https://doi.org/10.1038/labinvest.2017.17CrossRefPubMed

138.

Wang, Y., Wang, G., Zhang, X., Zhou, X., Liu, Z., Huang, L., Liu, R., Lang, B., Xu, X., Liu, W., et al. (2015). γ-Secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition. Molecular Medicine Reports, 12, 2821–2827. https://doi.org/10.3892/mmr.2015.3750CrossRefPubMed

139.

Baehrecke, E. H. (2005). Autophagy: Dual roles in life and death? Nature Reviews Molecular Cell Biology, 6, 505–510. https://doi.org/10.1038/nrm1666CrossRefPubMed

140.

Du, H., Tao, T., Xu, S., Xu, C., Li, S., Su, Q., Yan, J., Liu, B., & Li, R. (2021). 4-Methoxydalbergione inhibits bladder cancer cell growth via inducing autophagy and inhibiting Akt/ERK signaling pathway. Frontiers in Molecular Biosciences, 8, 789658. https://doi.org/10.3389/fmolb.2021.789658CrossRefPubMed

141.

Tsai, T. F., Chang, A. C., Chen, P. C., Ho, C. Y., Chen, H. E., Chou, K. Y., & Hwang, T. I. (2022). Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer. Journal of Cellular Physiology, 237, 3587–3597. https://doi.org/10.1002/jcp.30817CrossRefPubMed

142.

Amantini, C., Morelli, M. B., Nabissi, M., Cardinali, C., Santoni, M., Gismondi, A., & Santoni, G. (2016). Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an hedgehog-dependent manner. Oncotarget, 7, 50180–50194. https://doi.org/10.18632/oncotarget.10326CrossRefPubMedPubMedCentral

143.

Markouli, M., Strepkos, D., & Piperi, C. (2021). Structure, activity and function of the SETDB1 protein methyltransferase. Life (Basel), 11, 817. https://doi.org/10.3390/life11080817CrossRefPubMed

144.

Meng, X., Xiao, W., Sun, J., Li, W., Yuan, H., Yu, T., Zhang, X., & Dong, W. (2023). CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. Cancer Letters, 554, 216023. https://doi.org/10.1016/j.canlet.2022.216023CrossRefPubMed

145.

Kveiborg, M., Albrechtsen, R., Couchman, J. R., & Wewer, U. M. (2008). Cellular roles of ADAM12 in health and disease. International Journal of Biochemistry & Cell Biology, 40, 1685–1702. https://doi.org/10.1016/j.biocel.2008.01.025CrossRef

146.

Zhu, H., Jiang, W., Zhu, H., Hu, J., Tang, B., Zhou, Z., & He, X. (2022). Elevation of ADAM12 facilitates tumor progression by enhancing metastasis and immune infiltration in gastric cancer. International Journal of Oncology, 60, 1–13. https://doi.org/10.3892/ijo.2022.5341

147.

Wang, R., Gao, D., Chen, C., Fan, G., Cheng, H., Tao, Y., Lu, J., Tian, J., Wang, Y., & Wang, Z. (2022). ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-022-03044-xCrossRefPubMed

148.

Zhu, S., Xu, Z., Zeng, Y., Long, Y., Fan, G., Ding, Q., Wen, Y., Cao, J., Dai, T., Han, W., et al. (2020). ADNP upregulation promotes bladder cancer cell proliferation via the AKT pathway. Frontiers in Oncology, 10, 491129. https://doi.org/10.3389/fonc.2020.491129CrossRefPubMedPubMedCentral

149.

Xie, Y., Zhu, S., Zang, J., Wu, G., Wen, Y., Liang, Y., Long, Y., Guo, W., Zang, C., Hu, X., et al. (2021). ADNP prompts the cisplatin-resistance of bladder cancer via TGF-β-mediated epithelial-mesenchymal transition (EMT) pathway. Journal of Cancer, 12, 5114–5124. https://doi.org/10.7150/jca.58049CrossRefPubMedPubMedCentral

150.

Lu, Q., Yin, H., Deng, Y., Chen, W., Diao, W., Ding, M., Cao, W., Fu, Y., Mo, W., Chen, X., et al. (2022). circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5. Cell Death Discov, 8, 243. https://doi.org/10.1038/s41420-022-01037-xCrossRefPubMedPubMedCentral

151.

Lin, N., Chen, L., Zhang, Y., Yang, Y., Zhang, L., Chen, L., Zhang, P., Su, H., & Yin, M. (2022). KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment. Science and Reports, 12, 6015. https://doi.org/10.1038/s41598-022-10029-xCrossRef

152.

Wang, W., Zhang, M., Huang, Z., Wang, L., Yue, Y., Wang, X., Lu, S., & Fan, J. (2022). Knockdown of CXCL5 inhibits the invasion, metastasis and stemness of bladder cancer lung metastatic cells by downregulating CD44. Anti-Cancer Drugs, 33, e103–e112. https://doi.org/10.1097/cad.0000000000001153CrossRefPubMed

153.

Wang, C., Li, A., Yang, S., Qiao, R., Zhu, X., & Zhang, J. (2018). CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-κB pathway. Biochemical and Biophysical Research Communications, 498, 862–868. https://doi.org/10.1016/j.bbrc.2018.03.071CrossRefPubMed

154.

Xu, N., Xiao, W., Meng, X., Li, W., Wang, X., Zhang, X., & Yang, H. (2022). Up-regulation of SLC27A2 suppresses the proliferation and invasion of renal cancer by down-regulating CDK3-mediated EMT. Cell Death Discovery, 8, 351. https://doi.org/10.1038/s41420-022-01145-8CrossRefPubMedPubMedCentral

155.

Li, W., Xu, N., Meng, X., Yuan, H., Yu, T., Miao, Q., Yang, H., Hai, B., Xiao, W., & Zhang, X. (2023). SLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma. iScience, 26, 105764. https://doi.org/10.1016/j.isci.2022.105764CrossRefPubMed

156.

He, P., Dai, Q., & Wu, X. (2023). New insight in urological cancer therapy: From epithelial-mesenchymal transition (EMT) to application of nano-biomaterials. Environmental Research, 229, 115672. https://doi.org/10.1016/j.envres.2023.115672CrossRefPubMed

157.

Chen, J., Zhong, Y., & Li, L. (2020). miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC). Journal of Translational Medicine, 18, 69. https://doi.org/10.1186/s12967-020-02242-xCrossRefPubMedPubMedCentral

158.

Zhong, M., Zhu, M., Liu, Y., Lin, Y., Wang, L., Ye, Y., Chen, H., Yang, Y., Zhuang, G., & Huang, J. (2020). TNFAIP8 promotes the migration of clear cell renal cell carcinoma by regulating `the EMT. Journal of Cancer, 11, 3061–3071. https://doi.org/10.7150/jca.40191CrossRefPubMedPubMedCentral

159.

Gao, W., Zhang, S., Guorong, L., Liu, Q., Zhu, A., Gui, F., Zou, Y., Wu, Y., Luo, Y., & Hong, Z. (2022). Nc886 promotes renal cancer cell drug-resistance by enhancing EMT through Rock2 phosphorylation-mediated β-catenin nuclear translocation. Cell Cycle, 21, 340–351. https://doi.org/10.1080/15384101.2021.2020431CrossRefPubMedPubMedCentral

160.

Fang, L., Zhang, Y., Zang, Y., Chai, R., Zhong, G., Li, Z., Duan, Z., Ren, J., & Xu, Z. (2019). HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT. Carbohydrate Polymers, 223, 115109. https://doi.org/10.1016/j.carbpol.2019.115109CrossRefPubMed

161.

Que, T., Ren, B., Fan, Y., Liu, T., Hou, T., Dan, W., Liu, B., Wei, Y., Lei, Y., Zeng, J., et al. (2022). Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. Chemico-Biological Interactions, 366, 110043. https://doi.org/10.1016/j.cbi.2022.110043CrossRefPubMed

162.

Rees, J. R., Onwuegbusi, B. A., Save, V. E., Alderson, D., & Fitzgerald, R. C. (2006). In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Research, 66, 9583–9590. https://doi.org/10.1158/0008-5472.Can-06-1842CrossRefPubMed

163.

Kinugasa, H., Whelan, K. A., Tanaka, K., Natsuizaka, M., Long, A., Guo, A., Chang, S., Kagawa, S., Srinivasan, S., Guha, M., et al. (2015). Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression. Oncogene, 34, 5229–5239. https://doi.org/10.1038/onc.2014.449CrossRefPubMedPubMedCentral

164.

Ohashi, S., Natsuizaka, M., Wong, G. S., Michaylira, C. Z., Grugan, K. D., Stairs, D. B., Kalabis, J., Vega, M. E., Kalman, R. A., Nakagawa, M., et al. (2010). Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Research, 70, 4174–4184. https://doi.org/10.1158/0008-5472.Can-09-4614CrossRefPubMedPubMedCentral

165.

Liu, X., He, M., Li, L., Wang, X., Han, S., Zhao, J., Dong, Y., Ahmad, M., Li, L., Zhang, X., et al. (2021). EMT and cancer cell stemness associated with chemotherapeutic resistance in esophageal cancer. Frontiers in Oncology, 11, 672222. https://doi.org/10.3389/fonc.2021.672222CrossRefPubMedPubMedCentral

166.

Takaishi, S., Okumura, T., Tu, S., Wang, S. S., Shibata, W., Vigneshwaran, R., Gordon, S. A., Shimada, Y., & Wang, T. C. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells, 27, 1006–1020. https://doi.org/10.1002/stem.30CrossRefPubMed

167.

Bessède, E., Dubus, P., Mégraud, F., & Varon, C. (2015). Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene, 34, 2547–2555. https://doi.org/10.1038/onc.2014.187CrossRefPubMed

168.

Voon, D. C., Wang, H., Koo, J. K., Nguyen, T. A., Hor, Y. T., Chu, Y. S., Ito, K., Fukamachi, H., Chan, S. L., Thiery, J. P., et al. (2012). Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells, 30, 2088–2099. https://doi.org/10.1002/stem.1183CrossRefPubMed

169.

Cao, G., Li, P., He, X., Jin, M., Li, M., Chen, S., Xu, X., Sun, Q., Xiong, M., & Chen, B. (2021). FHL3 contributes to EMT and chemotherapy resistance through up-regulation of slug and activation of TGFβ/Smad-independent pathways in gastric cancer. Frontiers in Oncology, 11, 649029. https://doi.org/10.3389/fonc.2021.649029CrossRefPubMedPubMedCentral

170.

Chen, K., Xu, J., Tong, Y. L., Yan, J. F., Pan, Y., Wang, W. J., Zheng, L., Zheng, X. X., Hu, C., Hu, X., et al. (2023). Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT. Cell Death & Disease, 14, 115. https://doi.org/10.1038/s41419-023-05596-4CrossRef

171.

Mirone, G., Perna, S., Shukla, A., & Marfe, G. (2016). Involvement of Notch-1 in resistance to regorafenib in colon cancer cells. Journal of Cellular Physiology, 231, 1097–1105. https://doi.org/10.1002/jcp.25206CrossRefPubMed

172.

Ren, Y., Tao, J., Jiang, Z., Guo, D., & Tang, J. (2018). Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway. Life Sciences, 209, 267–273. https://doi.org/10.1016/j.lfs.2018.08.027CrossRefPubMed

173.

Zhou, H., Lin, C., Zhang, Y., Zhang, X., Zhang, C., Zhang, P., Xie, X., & Ren, Z. (2017). miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Proliferation, 50, e12341. https://doi.org/10.1111/cpr.12341

174.

Wang, H., Li, J. M., Wei, W., Yang, R., Chen, D., Ma, X. D., Jiang, G. M., & Wang, B. L. (2020). Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer. Cancer Science, 111, 84–97. https://doi.org/10.1111/cas.14253CrossRefPubMed

175.

Marquardt, J. U., Seo, D., Andersen, J. B., Gillen, M. C., Kim, M. S., Conner, E. A., Galle, P. R., Factor, V. M., Park, Y. N., & Thorgeirsson, S. S. (2014). Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. Journal of Hepatology, 60, 346–353. https://doi.org/10.1016/j.jhep.2013.10.014CrossRefPubMed

176.

Cozzolino, A. M., Alonzi, T., Santangelo, L., Mancone, C., Conti, B., Steindler, C., Musone, M., Cicchini, C., Tripodi, M., & Marchetti, A. (2013). TGFβ overrides HNF4α tumor suppressing activity through GSK3β inactivation: Implication for hepatocellular carcinoma gene therapy. Journal of Hepatology, 58, 65–72. https://doi.org/10.1016/j.jhep.2012.08.023CrossRefPubMed

177.

Zhang, Y., Cao, N., Gao, J., Liang, J., Liang, Y., Xie, Y., Zhou, S., & Tang, X. (2022). ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. Journal of Cellular and Molecular Medicine, 26, 2777–2792. https://doi.org/10.1111/jcmm.17288CrossRefPubMedPubMedCentral

178.

Campo, L., Zhang, C., & Breuer, E. K. (2015). EMT-inducing molecular factors in gynecological cancers. BioMed Research International, 2015, 420891. https://doi.org/10.1155/2015/420891CrossRefPubMedPubMedCentral

179.

Shibata, K., Kajiyama, H., Ino, K., Terauchi, M., Yamamoto, E., Nawa, A., Nomura, S., & Kikkawa, F. (2008). Twist expression in patients with cervical cancer is associated with poor disease outcome. Annals of Oncology, 19, 81–85. https://doi.org/10.1093/annonc/mdm344CrossRefPubMed

180.

Li, Y., Wang, W., Wang, W., Yang, R., Wang, T., Su, T., Weng, D., Tao, T., Li, W., Ma, D., et al. (2012). Correlation of TWIST2 up-regulation and epithelial-mesenchymal transition during tumorigenesis and progression of cervical carcinoma. Gynecologic Oncology, 124, 112–118. https://doi.org/10.1016/j.ygyno.2011.09.003CrossRefPubMed

181.

Li, J., & Zhou, B. P. (2011). Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer, 11, 49. https://doi.org/10.1186/1471-2407-11-49CrossRefPubMedPubMedCentral

182.

Kyo, S., Sakaguchi, J., Ohno, S., Mizumoto, Y., Maida, Y., Hashimoto, M., Nakamura, M., Takakura, M., Nakajima, M., Masutomi, K., et al. (2006). High twist expression is involved in infiltrative endometrial cancer and affects patient survival. Human Pathology, 37, 431–438. https://doi.org/10.1016/j.humpath.2005.12.021CrossRefPubMed

183.

Davidowitz, R. A., Selfors, L. M., Iwanicki, M. P., Elias, K. M., Karst, A., Piao, H., Ince, T. A., Drage, M. G., Dering, J., Konecny, G. E., et al. (2014). Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation, 124, 2611–2625. https://doi.org/10.1172/jci69815CrossRefPubMedPubMedCentral

184.

Rodrigues, I. S., Lavorato-Rocha, A. M., de, M. M. B., Stiepcich, M. M., de Carvalho, F. M., Baiocchi, G., Soares, F. A., Rocha, R. M. (2013). Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV. British Journal of Cancer, 109: 184–194, https://doi.org/10.1038/bjc.2013.273.

185.

Dong, P., Kaneuchi, M., Xiong, Y., Cao, L., Cai, M., Liu, X., Guo, S. W., Ju, J., Jia, N., Konno, Y., et al. (2014). Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis, 35, 760–768. https://doi.org/10.1093/carcin/bgt369CrossRefPubMed

186.

Chen, Z., Wang, Y., Liu, W., Zhao, G., Lee, S., Balogh, A., Zou, Y., Guo, Y., Zhang, Z., Gu, W., et al. (2014). Doxycycline inducible Krüppel-like factor 4 lentiviral vector mediates mesenchymal to epithelial transition in ovarian cancer cells. PLoS One, 9, e105331. https://doi.org/10.1371/journal.pone.0105331CrossRefPubMedPubMedCentral

187.

Touboul, C., Lis, R., Al Farsi, H., Raynaud, C. M., Warfa, M., Althawadi, H., Mery, E., Mirshahi, M., & Rafii, A. (2013). Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. Journal of Translational Medicine, 11, 28. https://doi.org/10.1186/1479-5876-11-28CrossRefPubMedPubMedCentral

188.

Miao, J. W., Liu, L. J., & Huang, J. (2014). Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. International Journal of Oncology, 45, 165–176. https://doi.org/10.3892/ijo.2014.2422CrossRefPubMed

189.

Hiss, D. (2012). Optimizing molecular-targeted therapies in ovarian cancer: The renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. Journal of Oncology, 2012, 737981. https://doi.org/10.1155/2012/737981CrossRefPubMedPubMedCentral

190.

Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H. (2019). Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacology & Therapeutics, 194, 161–184. https://doi.org/10.1016/j.pharmthera.2018.09.007CrossRef

191.

Bierie, B., Pierce, S. E., Kroeger, C., Stover, D. G., Pattabiraman, D. R., Thiru, P., Liu Donaher, J., Reinhardt, F., Chaffer, C. L., Keckesova, Z., et al. (2017). Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc Natl Acad Sci U S A, 114, E2337-e2346. https://doi.org/10.1073/pnas.1618298114CrossRefPubMedPubMedCentral

192.

Feng, Y. X., Sokol, E. S., Del Vecchio, C. A., Sanduja, S., Claessen, J. H., Proia, T. A., Jin, D. X., Reinhardt, F., Ploegh, H. L., Wang, Q., et al. (2014). Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stress. Cancer Discovery, 4, 702–715. https://doi.org/10.1158/2159-8290.Cd-13-0945CrossRefPubMed

193.

Lei, J. T., Shao, J., Zhang, J., Iglesia, M., Chan, D. W., Cao, J., Anurag, M., Singh, P., He, X., Kosaka, Y., et al. (2018). Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. Cell Reports, 24, 1434-1444.e1437. https://doi.org/10.1016/j.celrep.2018.07.009CrossRefPubMed

194.

Dong, C. Y., Liu, X. Y., Wang, N., Wang, L. N., Yang, B. X., Ren, Q., Liang, H. Y., & Ma, X. T. (2014). Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells, 32, 3173–3182. https://doi.org/10.1002/stem.1803CrossRefPubMed

195.

Chen, C. C., You, J. Y., Gau, J. P., Huang, C. E., Chen, Y. Y., Tsai, Y. H., Chou, H. J., Lung, J., & Yang, M. H. (2015). Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. Blood Cancer Journal, 5, e339. https://doi.org/10.1038/bcj.2015.67CrossRefPubMedPubMedCentral

196.

Inaba, T., Inukai, T., Yoshihara, T., Seyschab, H., Ashmun, R. A., Canman, C. E., Laken, S. J., Kastan, M. B., & Look, A. T. (1996). Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature, 382, 541–544. https://doi.org/10.1038/382541a0CrossRefPubMed

197.

Wang, N., Guo, D., Zhao, Y. Y., Dong, C. Y., Liu, X. Y., Yang, B. X., Wang, S. W., Wang, L., Liu, Q. G., Ren, Q., et al. (2015). TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. Oncotarget, 6, 20977–20992. https://doi.org/10.18632/oncotarget.4007CrossRefPubMedPubMedCentral

198.

Cosset, E., Hamdan, G., Jeanpierre, S., Voeltzel, T., Sagorny, K., Hayette, S., Mahon, F. X., Dumontet, C., Puisieux, A., Nicolini, F. E., et al. (2011). Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, 117, 1673–1676. https://doi.org/10.1182/blood-2009-11-254680CrossRefPubMed

199.

Pérez-Mancera, P. A., González-Herrero, I., Pérez-Caro, M., Gutiérrez-Cianca, N., Flores, T., Gutiérrez-Adán, A., Pintado, B., Sánchez-Martín, M., & Sánchez-García, I. (2005). SLUG in cancer development. Oncogene, 24, 3073–3082. https://doi.org/10.1038/sj.onc.1208505CrossRefPubMed

200.

Dorn, D. C., Kou, C. A., Png, K. J., & Moore, M. A. (2009). The effect of cantharidins on leukemic stem cells. International Journal of Cancer, 124, 2186–2199. https://doi.org/10.1002/ijc.24157CrossRefPubMed

201.

Wei, C. R., Liu, J., & Yu, X. J. (2015). Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. International Journal of Clinical and Experimental Medicine, 8, 22139–22148.PubMedPubMedCentral

202.

Mancini, M., Petta, S., Iacobucci, I., Salvestrini, V., Barbieri, E., & Santucci, M. A. (2010). Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cellular Signalling, 22, 1247–1253. https://doi.org/10.1016/j.cellsig.2010.04.002CrossRefPubMed

203.

Pérez-Mancera, P. A., Pérez-Caro, M., González-Herrero, I., Flores, T., Orfao, A., de Herreros, A. G., Gutiérrez-Adán, A., Pintado, B., Sagrera, A., Sánchez-Martín, M., et al. (2005). Cancer development induced by graded expression of Snail in mice. Human Molecular Genetics, 14, 3449–3461. https://doi.org/10.1093/hmg/ddi373CrossRefPubMed

204.

Li, H., Mar, B. G., Zhang, H., Puram, R. V., Vazquez, F., Weir, B. A., Hahn, W. C., Ebert, B., & Pellman, D. (2017). The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood, the Journal of the American Society of Hematology, 129, 497–508.

205.

Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020). EMT, MET, plasticity, and tumor metastasis. Trends in Cell Biology, 30, 764–776. https://doi.org/10.1016/j.tcb.2020.07.003CrossRefPubMedPubMedCentral

206.

Tang, Y., Durand, S., Dalle, S., & Caramel, J. (2020). EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment. Cancers (Basel), 12, 2154. https://doi.org/10.3390/cancers12082154CrossRefPubMed

207.

Wang, H., Wang, Z., Li, Y., Lu, T., & Hu, G. (2020). Silencing snail reverses epithelial-mesenchymal transition and increases radiosensitivity in hypopharyngeal carcinoma. Oncotargets and Therapy, 13, 497–511. https://doi.org/10.2147/ott.S237410CrossRefPubMedPubMedCentral

208.

Jiang, F., Zhou, L., Wei, C., Zhao, W., & Yu, D. (2016). Slug inhibition increases radiosensitivity of oral squamous cell carcinoma cells by upregulating PUMA. International Journal of Oncology, 49, 709–719. https://doi.org/10.3892/ijo.2016.3570CrossRefPubMed

209.

Shahin, S. A., Wang, R., Simargi, S. I., Contreras, A., Parra Echavarria, L., Qu, L., Wen, W., Dellinger, T., Unternaehrer, J., Tamanoi, F., et al. (2018). Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine, 14, 1381–1394. https://doi.org/10.1016/j.nano.2018.04.008CrossRefPubMed

210.

Wang, M., He, S. F., Liu, L. L., Sun, X. X., Yang, F., Ge, Q., Wong, W. K., & Meng, J. Y. (2017). Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling. Oncology Reports, 38, 1941–1948. https://doi.org/10.3892/or.2017.5888CrossRefPubMedPubMedCentral

211.

Hao, Y., Baker, D., & Ten Dijke, P. (2019). TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. International Journal of Molecular Sciences, 20, 2767. https://doi.org/10.3390/ijms20112767CrossRefPubMedPubMedCentral

212.

Bayin, N. S., Ma, L., Thomas, C., Baitalmal, R., Sure, A., Fansiwala, K., Bustoros, M., Golfinos, J. G., Pacione, D., Snuderl, M., et al. (2016). Patient-specific screening using high-grade glioma explants to determine potential radiosensitization by a TGF-β small molecule inhibitor. Neoplasia, 18, 795–805. https://doi.org/10.1016/j.neo.2016.08.008CrossRefPubMedPubMedCentral

213.

Zhang, J., Si, J., Gan, L., Guo, M., Yan, J., Chen, Y., Wang, F., Xie, Y., Wang, Y., & Zhang, H. (2020). Inhibition of Wnt signalling pathway by XAV939 enhances radiosensitivity in human cervical cancer HeLa cells. Artificial Cells, Nanomedicine, and Biotechnology, 48, 479–487. https://doi.org/10.1080/21691401.2020.1716779CrossRefPubMed

214.

Prakash, V., Carson, B. B., Feenstra, J. M., Dass, R. A., Sekyrova, P., Hoshino, A., Petersen, J., Guo, Y., Parks, M. M., Kurylo, C. M., et al. (2019). Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nature Communications, 10, 2110. https://doi.org/10.1038/s41467-019-10100-8CrossRefPubMedPubMedCentral

215.

Dermit, M., Dodel, M., Lee, F. C. Y., Azman, M. S., Schwenzer, H., Jones, J. L., Blagden, S. P., Ule, J., & Mardakheh, F. K. (2020). Subcellular mRNA localization regulates ribosome biogenesis in migrating cells. Developmental Cell, 55, 298-313.e210. https://doi.org/10.1016/j.devcel.2020.10.006CrossRefPubMedPubMedCentral

216.

Pecoraro, A., Carotenuto, P., Russo, G., & Russo, A. (2019). Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress. Science and Reports, 9, 15431. https://doi.org/10.1038/s41598-019-51723-7CrossRef

217.

Mattijssen, S., Arimbasseri, A. G., Iben, J. R., Gaidamakov, S., Lee, J., Hafner, M., & Maraia, R. J. (2017). LARP4 mRNA codon-tRNA match contributes to LARP4 activity for ribosomal protein mRNA poly(A) tail length protection. Elife, 6, e28889. https://doi.org/10.7554/eLife.28889

Titel: Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response
verfasst von: Nasim Ebrahimi
Mahdokht Sadat Manavi
Ferdos Faghihkhorasani
Siavash Seifollahy Fakhr
Fatemeh Jafari Baei
Fereshteh Faghih Khorasani
Mohammad Mehdi Zare
Nazanin Pazhouhesh Far
Fatemeh Rezaei-Tazangi
Jun Ren
Russel J. Reiter
Noushin Nabavi
Amir Reza Aref
Chu Chen
Yavuz Nuri Ertas
Qi Lu
Publikationsdatum: 16.01.2024
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10162-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

Preface

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie